Inhibition of HDAC1 and DNMT1 modulate RGS10 expression and decrease ovarian cancer chemoresistance

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Cacan, Ercan ^a   Ali, Mourad W ^b   Boyd, Nathaniel H ^a   Hooks, Shelley B ^b   Greer, Susanna F ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CISPLATIN; DNA METHYLTRANSFERASE 1; HISTONE DEACETYLASE 1; RGS PROTEIN; RGS10 PROTEIN; TRICHOSTATIN A; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL VIABILITY; CONTROLLED STUDY; HISTONE ACETYLATION; OVARIAN CANCER CELL LINE; PROMOTER REGION; PROTEIN EXPRESSION;

CHROMATIN IMMUNOPRECIPITATION; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA PRIMERS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE 1; HUMANS; OVARIAN NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; RGS PROTEINS; RNA, SMALL INTERFERING;

EID: 84900344547     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087455     Document Type: Article

References (79)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63: 11-30.
2. Hooks SB, Callihan P, Altman MK, Hurst JH, Ali MW, et al. (2010) Regulators of G-Protein signaling RGS10 and RGS17 regulate chemoresistance in ovarian cancer cells. Mol Cancer 9: 289.
3. Liu B, Nash J, Runowicz C, Swede H, Stevens R, et al. (2010) Ovarian cancer immunotherapy: opportunities, progresses and challenges. J Hematol Oncol 3: 7.
4. Cai H, Xu Y (2013) The role of LPA and YAP signaling in long-term migration of human ovarian cancer cells. Cell Commun Signal 11: 31.
5. O'Hayre M, Vazquez-Prado J, Kufareva I, Stawiski EW, Handel TM, et al. (2013) The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer. Nat Rev Cancer 13: 412-424.
6. Hurst JH, Hooks SB (2009) Lysophosphatidic acid stimulates cell growth by different mechanisms in SKOV-3 and Caov-3 ovarian cancer cells: distinct roles for Gi- and Rho-dependent pathways. Pharmacology 83: 333-347.
7. Zhong H, Neubig RR (2001) Regulator of G protein signaling proteins: novel multifunctional drug targets. J Pharmacol Exp Ther 297: 837-845. (Pubitemid 32472477)
8. Shi GX, Harrison K, Han SB, Moratz C, Kehrl JH (2004) Toll-like receptor signaling alters the expression of regulator of G protein signaling proteins in dendritic cells: implications for G protein-coupled receptor signaling. J Immunol 172: 5175-5184. (Pubitemid 38542013)
9. Berman DM, Gilman AG (1998) Mammalian RGS proteins: barbarians at the gate. J Biol Chem 273: 1269-1272. (Pubitemid 28133638)
10. Hurst JH, Hooks SB (2009) Regulator of G-protein signaling (RGS) proteins in cancer biology. Biochem Pharmacol 78: 1289-1297.
11. Xie Y, Wolff DW, Wei T, Wang B, Deng C, et al. (2009) Breast cancer migration and invasion depend on proteasome degradation of regulator of G-protein signaling 4. Cancer Res 69: 5743-5751.
12. Liang G, Bansal G, Xie Z, Druey KM (2009) RGS16 inhibits breast cancer cell growth by mitigating phosphatidylinositol 3-kinase signaling. J Biol Chem 284: 21719-21727.
13. Bodle CR, Mackie DI, Roman DL (2013) RGS17: an emerging therapeutic target for lung and prostate cancers. Future Med Chem 5: 995-1007.
14. Cao X, Qin J, Xie Y, Khan O, Dowd F, et al. (2006) Regulator of G-protein signaling 2 (RGS2) inhibits androgen-independent activation of androgen receptor in prostate cancer cells. Oncogene 25: 3719-3734. (Pubitemid 43980493)
15. Ali MW, Cacan E, Liu Y, Pierce JY, Creasman WT, et al. (2013) Transcriptional suppression, DNA methylation, and histone deacetylation of the regulator of G-protein signaling 10 (RGS10) gene in ovarian cancer cells. PLoS One 8: e60185.
16. Lee JK, Chung J, Druey KM, Tansey MG (2012) RGS10 exerts a neuroprotective role through the PKA/c-AMP response-element (CREB) pathway in dopaminergic neuron-like cells. J Neurochem 122: 333-343.
17. Rivero G, Gabilondo AM, Garcia-Sevilla JA, Callado LF, La Harpe R, et al. (2013) Brain RGS4 and RGS10 protein expression in schizophrenia and depression. Effect of drug treatment. Psychopharmacology (Berl) 226: 177-188.
18. Garcia-Bernal D, Dios-Esponera A, Sotillo-Mallo E, Garcia-Verdugo R, Arellano-Sanchez N, et al. (2011) RGS10 restricts upregulation by chemokines of T cell adhesion mediated by alpha4beta1 and alphaLbeta2 integrins. J Immunol 187: 1264-1272.
19. Lu J, Gosslau A, Liu AY, Chen KY (2008) PCR differential display-based identification of regulator of G protein signaling 10 as the target gene in human colon cancer cells induced by black tea polyphenol theaflavin monogallate. Eur J Pharmacol 601: 66-72.
20. Rhee I, Jair KW, Yen RW, Lengauer C, Herman JG, et al. (2000) CpG methylation is maintained in human cancer cells lacking DNMT1. Nature 404: 1003-1007. (Pubitemid 30243595)
21. Ito K, P JB, I MA (2000) Histone acetylation and deacetylation. Methods Mol Med 44: 309-319.
22. Ghoshal K, Datta J, Majumder S, Bai S, Dong X, et al. (2002) Inhibitors of histone deacetylase and DNA methyltransferase synergistically activate the methylated metallothionein I promoter by activating the transcription factor MTF-1 and forming an open chromatin structure. Mol Cell Biol 22: 8302-8319. (Pubitemid 35304062)
23. Cai Y, Geutjes EJ, de Lint K, Roepman P, Bruurs L, et al. (2013) The NuRD complex cooperates with DNMTs to maintain silencing of key colorectal tumor suppressor genes. Oncogene.
24. Fuks F, Burgers WA, Brehm A, Hughes-Davies L, Kouzarides T (2000) DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat Genet 24: 88-91. (Pubitemid 30041428)
25. Louie KG, Behrens BC, Kinsella TJ, Hamilton TC, Grotzinger KR, et al. (1985) Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. Cancer Res 45: 2110-2115. (Pubitemid 15024393)
26. DiSaia PJ, Sinkovics JG, Rutledge FN, Smith JP (1972) Cell-mediated immunity to human malignant cells. A brief review and further studies with two gynecologic tumors. Am J Obstet Gynecol 114: 979-989.
27. Andrews PA, Murphy MP, Howell SB (1985) Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion. Cancer Res 45: 6250-6253. (Pubitemid 16224789)
28. Manuyakorn A, Paulus R, Farrell J, Dawson NA, Tze S, et al. (2010) Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704. J Clin Oncol 28: 1358-1365.
29. Seligson DB, Horvath S, McBrian MA, Mah V, Yu H, et al. (2009) Global levels of histone modifications predict prognosis in different cancers. Am J Pathol 174: 1619-1628.
30. Zwaal RF, Schroit AJ (1997) Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 89: 1121-1132. (Pubitemid 27079974)
31. van Engeland M, Nieland LJ, Ramaekers FC, Schutte B, Reutelingsperger CP (1998) Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 31: 1-9. (Pubitemid 28050057)
32. Modest EJ, Sengupta SK (1974) 7-Substituted actinomycin D (NSC-3053) analogs as fluorescent DNA-binding and experimental antitumor agents. Cancer Chemother Rep 58: 35-48.
33. Ballestar E, Esteller M (2002) The impact of chromatin in human cancer: linking DNA methylation to gene silencing. Carcinogenesis 23: 1103-1109. (Pubitemid 34814766)
34. Robertson KD, Ait-Si-Ali S, Yokochi T, Wade PA, Jones PL, et al. (2000) DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat Genet 25: 338-342. (Pubitemid 30437325)
35. Di Croce L, Raker VA, Corsaro M, Fazi F, Fanelli M, et al. (2002) Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 295: 1079-1082. (Pubitemid 34132239)
36. Fuks F, Burgers WA, Godin N, Kasai M, Kouzarides T (2001) Dnmt3a binds deacetylases and is recruited by a sequence-specific repressor to silence transcription. EMBO J 20: 2536-2544. (Pubitemid 32452872)
37. Zhou Q, Agoston AT, Atadja P, Nelson WG, Davidson NE (2008) Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells. Mol Cancer Res 6: 873-883.
38. Vaissiere T, Sawan C, Herceg Z (2008) Epigenetic interplay between histone modifications and DNA methylation in gene silencing. Mutat Res 659: 40-48.
39. Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, et al. (1998) Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 19: 187-191. (Pubitemid 28248804)
40. Jones PL, Wade PA, Wolffe AP (2001) Purification of the MeCP2/histone deacetylase complex from Xenopus laevis. Methods Mol Biol 181: 297-307.
41. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, et al. (1998) Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393: 386-389. (Pubitemid 28269714)
42. Carrieri A, Perez-Nueno VI, Lentini G, Ritchie DW (2013) Recent Trends and Future Prospects in Computational GPCR Drug Discovery: From Virtual Screening to Polypharmacology. Curr Top Med Chem 13: 1069-1097.
43. Xie Y, Abel PW, Kirui JK, Deng C, Sharma P, et al. (2013) Identification of upregulated phosphoinositide 3-kinase gamma as a target to suppress breast cancer cell migration and invasion. Biochem Pharmacol 85: 1454-1462.
44. Gold SJ, Heifets BD, Pudiak CM, Potts BW, Nestler EJ (2002) Regulation of regulators of G protein signaling mRNA expression in rat brain by acute and chronic electroconvulsive seizures. J Neurochem 82: 828-838.
45. Hunt TW, Fields TA, Casey PJ, Peralta EG (1996) RGS10 is a selective activator of G alpha i GTPase activity. Nature 383: 175-177. (Pubitemid 26303981)
46. Popov S, Yu K, Kozasa T, Wilkie TM (1997) The regulators of G protein signaling (RGS) domains of RGS4, RGS10, and GAIP retain GTPase activating protein activity in vitro. Proc Natl Acad Sci U S A 94: 7216-7220. (Pubitemid 27345295)
47. Robertson KD (2005) DNA methylation and human disease. Nat Rev Genet 6: 597-610.
48. Fuks F (2005) DNA methylation and histone modifications: teaming up to silence genes. Curr Opin Genet Dev 15: 490-495.
49. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, et al. (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343: 1350-1354.
50. Giacinti L, Vici P, Lopez M (2008) Epigenome: a new target in cancer therapy. Clin Ter 159: 347-360.
51. Zeller C, Dai W, Steele NL, Siddiq A, Walley AJ, et al. (2012) Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Oncogene 31: 4567-4576.
52. Stronach EA, Alfraidi A, Rama N, Datler C, Studd JB, et al. (2011) HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. Cancer Res 71: 4412-4422.
53. Terasawa K, Sagae S, Toyota M, Tsukada K, Ogi K, et al. (2004) Epigenetic inactivation of TMS1/ASC in ovarian cancer. Clin Cancer Res 10: 2000-2006. (Pubitemid 38375559)
54. Barneda-Zahonero B, Parra M (2012) Histone deacetylases and cancer. Mol Oncol 6: 579-589.
55. Hassig CA, Schreiber SL (1997) Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs. Curr Opin Chem Biol 1: 300-308. (Pubitemid 127437155)
56. Kruhlak MJ, Hendzel MJ, Fischle W, Bertos NR, Hameed S, et al. (2001) Regulation of global acetylation in mitosis through loss of histone acetyltransferases and deacetylases from chromatin. J Biol Chem 276: 38307-38319.
57. Marks PA, Miller T, Richon VM (2003) Histone deacetylases. Curr Opin Pharmacol 3: 344-351. (Pubitemid 36908937)
58. Arts J, Angibaud P, Marien A, Floren W, Janssens B, et al. (2007) R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies. Br J Cancer 97: 1344-1353. (Pubitemid 350114783)
59. Witt O, Deubzer HE, Milde T, Oehme I (2009) HDAC family: What are the cancer relevant targets? Cancer Lett 277: 8-21.
60. Wang C, Henkes LM, Doughty LB, He M, Wang D, et al. (2011) Thailandepsins: bacterial products with potent histone deacetylase inhibitory activities and broad-spectrum antiproliferative activities. J Nat Prod 74: 2031-2038.
61. Jin B, Yao B, Li JL, Fields CR, Delmas AL, et al. (2009) DNMT1 and DNMT3B modulate distinct polycomb-mediated histone modifications in colon cancer. Cancer Res 69: 7412-7421.
62. Muller BM, Jana L, Kasajima A, Lehmann A, Prinzler J, et al. (2013) Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer-overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression. BMC Cancer 13: 215.
63. Herman JG, Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349: 2042-2054. (Pubitemid 37448928)
64. Esteller M (2007) Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 8: 286-298.
65. Nguyen CT, Gonzales FA, Jones PA (2001) Altered chromatin structure associated with methylation-induced gene silencing in cancer cells: correlation of accessibility, methylation, MeCP2 binding and acetylation. Nucleic Acids Res 29: 4598-4606. (Pubitemid 33095020)
66. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB (1999) Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21: 103-107. (Pubitemid 29036293)
67. Meng CF, Su B, Li W (2011) DNA demethylation is superior to histone acetylation for reactivating cancer-associated genes in ovarian cancer cells. Mol Med Rep 4: 1273-1278.
68. Gu Y, Yang P, Shao Q, Liu X, Xia S, et al. (2013) Investigation of the expression patterns and correlation of DNA methyltransferases and class I histone deacetylases in ovarian cancer tissues. Oncol Lett 5: 452-458.
69. Kimura H, Shiota K (2003) Methyl-CpG-binding protein, MeCP2, is a target molecule for maintenance DNA methyltransferase, Dnmt1. J Biol Chem 278: 4806-4812. (Pubitemid 36800984)
70. Herzog TJ, Sill MW, Walker JL, O'Malley D, Shahin M, et al. (2011) A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q). Gynecol Oncol 120: 454-458.
71. Dear RF, Gao B, Harnett P (2010) Recurrent ovarian cancer: treatment with pegylated liposomal doxorubicin; a Westmead Cancer Care Centre experience. Asia Pac J Clin Oncol 6: 66-73.
72. Carafa V, Nebbioso A, Altucci L (2011) Histone deacetylase inhibitors: recent insights from basic to clinical knowledge & patenting of anti-cancer actions. Recent Pat Anticancer Drug Discov 6: 131-145.
73. Espino PS, Drobic B, Dunn KL, Davie JR (2005) Histone modifications as a platform for cancer therapy. J Cell Biochem 94: 1088-1102. (Pubitemid 41420232)
74. Zhu WG, Otterson GA (2003) The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr Med Chem Anticancer Agents 3: 187-199.
75. Johnstone RW (2002) Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1: 287-299.
76. Takai N, Desmond JC, Kumagai T, Gui D, Said JW, et al. (2004) Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res 10: 1141-1149. (Pubitemid 38198916)
77. Lyko F, Brown R (2005) DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J Natl Cancer Inst 97: 1498-1506. (Pubitemid 41631949)
78. Meng F, Sun G, Zhong M, Yu Y, Brewer MA (2013) Inhibition of DNA methyltransferases, histone deacetylases and lysine-specific demethylase-1 suppresses the tumorigenicity of the ovarian cancer ascites cell line SKOV3. Int J Oncol 43: 495-502.
79. Falchook GS, Fu S, Naing A, Hong DS, Hu W, et al. (2013) Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies. Invest New Drugs.